Home Newsfeeds Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5

Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5

Cantor Fitzgerald downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and lowers the price target from $75 to $68.5.

byBenzinga Newsdesk

August 9, 2022

1 minute read

Cantor Fitzgerald downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and lowers the price target from $75 to $68.5.

Analyst Ratings

Forecasting The Future: 12 Analyst Projections For Molson Coors Beverage

By Benzinga Insights

May 1, 3:01 PM

During the last three months, 12 analysts shared their evaluations of Molson Coors Beverage (NYSE:TAP), revealing diverse outlooks…

TAP

Bitcoin Jumps To $22K, Ethereum, Dogecoin Rally As Team Biden Cushions SVB Blow: Analyst Sees Apex Crypto At $25K If It Breaks This Level

By Mehab Qureshi

March 12, 10:45 PM

Major coins traded in the green on Sunday evening following news that all Silicon Valley Bank and Signature Bank deposits will be fully refunded to customers.

$DOGE

Bitcoin Trades At $3K Discount, Ethereum Available $200 Cheaper On Binance.US — Jim Chanos Questions 10% Arbitrage Across Major Exchanges

By Mehab Qureshi

July 10, 3:43 AM

Bitcoin (CRYPTO: BTC) on Sunday faced a price discrepancy on the Binance.US crypto exchange, trading at a discount of nearly $3,000 compared to global spot prices.

BTC